Key result
The miR-132 inhibitor CDR132L was well-tolerated but did not improve ventricular remodelling compared with placebo in patients with myocardial infarction and reduced ejection fraction.
Why the study?
Does miR-132 inhibitor CDR132L improve ventricular remodelling in patients with myocardial infarction and reduced left ventricular ejection fraction?
Does miR-132 inhibitor CDR132L improve ventricular remodelling in patients with myocardial infarction and reduced left ventricular ejection fraction?
Answers are grounded in this paper and cite their sources.
The miR-132 inhibitor CDR132L demonstrated safety and target engagement but failed to improve ventricular remodeling in patients with MI and reduced LVEF.
In the randomized, phase II HF-REVERT trial, the miR-132 inhibitor CDR132L was well-tolerated and showed pharmacodynamic target engagement in patients with myocardial infarction and reduced left ventricular ejection fraction, but did not improve ventricular remodelling compared with placebo.
No takes yet. Share an insight, caveat, or question.
Karina Huynh (2026) studied this question. The miR-132 inhibitor CDR132L was well-tolerated but did not improve ventricular remodelling compared with placebo in patients with myocardial infarction and reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: